If you've started semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) and noticed your face looks different, your arms feel loose, or your skin just doesn't bounce back the way it used to — you're not imagining it, and you're not alone. An estimated 14 million U.S. adults are currently on a GLP-1 medication, and a growing body of peer-reviewed research is documenting exactly why skin changes so often come along with the weight loss.
Here's what's actually happening in your skin, and what your options are — including the honest answer about when skincare and supplements aren't enough on their own.
It’s not just “Ozempic face” — it’s whole-body
Most of the conversation about GLP-1 skin changes focuses on the face, and “Ozempic face” has become the shorthand for it: hollowed cheeks, sunken under-eyes, deeper nasolabial folds, a softer jawline. That’s real, but it’s only the most visible part of a bigger picture.
The same biology that reshapes your face is reshaping the skin on your arms, abdomen, and thighs. Facial volume loss just happens to be the part people notice first, because faces are the part of the body everyone sees every day. Underneath your sleeves, the story is the same: fat loss that outpaces skin’s ability to adapt, leaving loose, crepey, or sagging skin behind. Peer-reviewed literature on GLP-1 receptor agonists and skin now explicitly frames this as a whole-body phenomenon, not a facial one (Ridha et al., Aesthetic Surgery Journal, 2024; Paschou et al., Endocrine, 2025).
Four things happening under the surface
1. Fat loss outpaces skin’s ability to shrink back
GLP-1 medications can produce weight loss faster than skin — an organ that relies on collagen and elastin to hold its shape — can remodel to match. Facial fat pads that once cushioned your cheeks and under-eyes shrink. The same thing happens to the fat layer under the skin on your arms, stomach, and thighs. When the volume underneath disappears faster than the skin on top can tighten, you get hollowing in the face and looseness or crepiness in the body.
2. GLP-1 receptors sit directly in your skin — not just your gut
Most people know GLP-1 drugs work by binding to receptors in the gut and pancreas, which is how they slow digestion and blunt appetite. What’s less widely known: the same receptor also shows up in skin tissue itself. Researchers have identified GLP-1 receptors on adipose-derived stem cells and fibroblasts in the dermis — the layer that manufactures collagen and elastin — as well as on keratinocytes in the outer epidermis and in specific regions of hair follicles. That means your medication isn’t only reshaping your skin indirectly, by removing the fat pad underneath it — it may also be acting directly on the cells living inside your skin.
When GLP-1 activates those receptors, emerging research suggests it reduces the protective, collagen-supporting signals adipose-derived stem cells normally send to neighboring fibroblasts, increases oxidative stress, and impairs those cells’ energy production — an effect layered on top of, and separate from, the loss of fat volume itself. Skin biopsies in this research show measurable changes in collagen and elastic fiber density consistent with that direct cellular effect. Less collagen and elastin means skin that’s less able to snap back into place — a large part of why laxity, not just volume loss, is such a common complaint (Paschou et al., Endocrine, 2025; Ridha et al., Aesthetic Surgery Journal, 2024).
3. Reduced appetite means reduced raw materials for skin
GLP-1 drugs work in part by suppressing appetite, and when food intake drops, so does your supply of the nutrients skin depends on to repair and rebuild itself: protein (the literal building block of collagen), zinc and copper (needed for collagen cross-linking and repair), vitamin C (a required co-factor for collagen synthesis), iron, and essential fatty acids (critical to your skin’s moisture barrier). This isn’t a minor or occasional issue — one large cohort study of 461,382 patients found 12.7% developed a diagnosable nutritional deficiency within 6 months of starting GLP-1 therapy, rising to 22% by 12 months, with vitamin D, iron, and calcium/protein intake most commonly affected (Butsch et al., Obesity Pillars, 2025). Dermatology researchers have specifically flagged fatigue, hair shedding, skin flakiness, and slow wound healing as signs of these deficiencies showing up on the skin (Cartwright, AAD Annual Meeting, 2024).
4. The skin barrier itself gets disrupted
Your outer skin layer depends on dietary fat to hold moisture in. When overall fat intake drops — as it typically does on a reduced-appetite GLP-1 regimen — the raw materials your skin uses to build and maintain its barrier become scarce, and that barrier develops microscopic gaps. Water escapes more easily, and skin feels persistently dry, looks dull, and reacts more to things that never used to bother it. Omega-3 fatty acids are essential nutrients — your body can’t manufacture meaningful amounts on its own — and foundational nutrition research has long linked overall micronutrient and fatty acid intake to measurable skin condition (Boelsma et al., American Journal of Clinical Nutrition, 2001).
What this actually looks like
- Facial hollowing — sunken cheeks and under-eyes, deeper nose-to-mouth lines, a softer jawline
- Skin laxity — skin that feels less firm and appears to sag, most noticeable where fat was most concentrated
- Crepey texture — a fine, paper-like quality on the inner arms, abdomen, and thighs
- Persistent dryness — tightness or flaking that doesn’t resolve with regular moisturizer
- Hair thinning — documented in clinical trials for both Wegovy and Zepbound; one meta-analysis found roughly a threefold increase in hair-loss reports versus placebo (Gupta et al., SAGE Journals, 2026)
- Looking “older” or more tired — the combined visual effect of volume loss, thinner-feeling skin, and a compromised barrier
None of this means something has gone wrong. It’s a documented physiological response to rapid weight change and altered nutrition — not a sign your medication is failing you, and not something you caused.
What actually helps
Because the drivers are twofold — structural (fat and collagen loss) and nutritional (reduced intake) — the most effective response addresses both:
From the outside: targeted topical ingredients with real evidence behind them at the dermal level, not just generic anti-aging products built for sun damage and time. Retinol, peptides like Matrixyl 3000, multi-weight hyaluronic acid, and topical vitamin C all have documented activity relevant to what’s actually happening in GLP-1-affected skin.
From the inside: making sure protein, zinc, copper, vitamin C, iron, vitamin D, and omega-3 intake stay adequate even as overall food intake drops — through diet first, and supplementation where gaps remain.
Timing: starting earlier in treatment tends to work better than trying to reverse changes after they’ve accumulated, since you’re supporting skin through the process rather than repairing it afterward.
When skincare and supplements aren’t enough — and that’s okay
Here’s the part worth being honest about: topical products and nutritional support can meaningfully improve hydration, texture, and the appearance of firmness — but they cannot regenerate fat volume or reverse significant structural collagen and elastin loss. If you’ve lost a large amount of weight quickly, or your skin laxity is more pronounced, no cream, serum, or supplement is going to fully restore lost facial volume or tighten skin that has lost substantial elastic recoil. That’s not a failure of the product — it’s a limit of what a topical can physically do.
For more dramatic changes, procedural options exist and are worth discussing with a qualified provider:
- Dermal fillers (hyaluronic acid or biostimulatory fillers like poly-L-lactic acid) can restore lost facial volume directly, addressing hollowing that topicals can only soften.
- Energy-based skin-tightening devices (radiofrequency, ultrasound, or laser-based treatments) can stimulate collagen remodeling more aggressively than topical actives alone, for moderate laxity on the face or body.
- Surgical options — a facelift for significant facial laxity, or body-contouring procedures such as an arm lift, thigh lift, or abdominoplasty — are appropriate and common considerations when skin has lost too much structural integrity for non-surgical approaches to meaningfully correct.
None of these are an admission of failure, and none of them mean you did something wrong by losing weight the way your medication intended. They’re simply additional tools, and for some people — particularly after large or rapid weight loss — they’re the most realistic way to get the result a topical alone can’t deliver. A board-certified dermatologist or plastic surgeon can help you figure out where your own changes fall on that spectrum.